Cargando…

Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects

BACKGROUND: The linkage between IDO2 expression and cancer progression is still unclear, particularly in medullary thyroid carcinoma (MTC). Our purpose is to unveil the potential correlations between IDO2 status, clinical-pathological parameters, patients’ prognosis, and the possible immunomodulator...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Pengfei, Ling, Bin, Ma, Weike, Zhang, Jinming, Zhang, Wei, Zeng, Yu, Liu, Yu, Chi, Jiadong, Ruan, Xianhui, Zheng, Xiangqian, Wei, Songfeng, Gao, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624013/
https://www.ncbi.nlm.nih.gov/pubmed/36319978
http://dx.doi.org/10.1186/s12885-022-10173-7
_version_ 1784822136951537664
author Gu, Pengfei
Ling, Bin
Ma, Weike
Zhang, Jinming
Zhang, Wei
Zeng, Yu
Liu, Yu
Chi, Jiadong
Ruan, Xianhui
Zheng, Xiangqian
Wei, Songfeng
Gao, Ming
author_facet Gu, Pengfei
Ling, Bin
Ma, Weike
Zhang, Jinming
Zhang, Wei
Zeng, Yu
Liu, Yu
Chi, Jiadong
Ruan, Xianhui
Zheng, Xiangqian
Wei, Songfeng
Gao, Ming
author_sort Gu, Pengfei
collection PubMed
description BACKGROUND: The linkage between IDO2 expression and cancer progression is still unclear, particularly in medullary thyroid carcinoma (MTC). Our purpose is to unveil the potential correlations between IDO2 status, clinical-pathological parameters, patients’ prognosis, and the possible immunomodulatory functions in MTC. METHODS: Immunohistochemical expression levels of IDO2 were evaluated in the resected MTC surgical specimens and corresponding lymph nodes. CD4 + T cell infiltration was also evaluated by immunohistochemical analysis in the MTC tissues. The association of the IDO2 expression level with clinicopathologic characteristics, overall survival (OS)/recurrence-free survival (RFS), and CD4 + T cell infiltration were retrospectively investigated. RESULTS: High expression of IDO2 is closely associated with more aggressive clinicopathological features, such as multifocality, ETE, a higher pT stage and especially a higher pN stage. Moreover, a significant difference in RFS was observed between the IDO2-high and IDO2-low groups. IDO2 expression of lymph node tissues was significantly related to the metastasis status. Furthermore, we found that IDO2 expression is negatively correlated with CD4 + T cell infiltrations in MTC tissues. CONCLUSION: The expression level of IDO2 is associated with aggressive characteristics and is predictive of poor prognosis in patients with MTC. Also, an interesting observation is that IDO2 involvement in MTC showed a moderate sexual dimorphism, of which female patients tend to be more affected by IDO2 status. Moreover, our results showed the potential immunomodulatory functions of IDO2. The close relationship between IDO2 and CD4 + T cell infiltration in the MTC microenvironment, together with its potential prognostic implications, makes it possible for IDO2 to serve as an alternative drug target in cancer immunotherapy and as a new prognostic tool.
format Online
Article
Text
id pubmed-9624013
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96240132022-11-02 Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects Gu, Pengfei Ling, Bin Ma, Weike Zhang, Jinming Zhang, Wei Zeng, Yu Liu, Yu Chi, Jiadong Ruan, Xianhui Zheng, Xiangqian Wei, Songfeng Gao, Ming BMC Cancer Research BACKGROUND: The linkage between IDO2 expression and cancer progression is still unclear, particularly in medullary thyroid carcinoma (MTC). Our purpose is to unveil the potential correlations between IDO2 status, clinical-pathological parameters, patients’ prognosis, and the possible immunomodulatory functions in MTC. METHODS: Immunohistochemical expression levels of IDO2 were evaluated in the resected MTC surgical specimens and corresponding lymph nodes. CD4 + T cell infiltration was also evaluated by immunohistochemical analysis in the MTC tissues. The association of the IDO2 expression level with clinicopathologic characteristics, overall survival (OS)/recurrence-free survival (RFS), and CD4 + T cell infiltration were retrospectively investigated. RESULTS: High expression of IDO2 is closely associated with more aggressive clinicopathological features, such as multifocality, ETE, a higher pT stage and especially a higher pN stage. Moreover, a significant difference in RFS was observed between the IDO2-high and IDO2-low groups. IDO2 expression of lymph node tissues was significantly related to the metastasis status. Furthermore, we found that IDO2 expression is negatively correlated with CD4 + T cell infiltrations in MTC tissues. CONCLUSION: The expression level of IDO2 is associated with aggressive characteristics and is predictive of poor prognosis in patients with MTC. Also, an interesting observation is that IDO2 involvement in MTC showed a moderate sexual dimorphism, of which female patients tend to be more affected by IDO2 status. Moreover, our results showed the potential immunomodulatory functions of IDO2. The close relationship between IDO2 and CD4 + T cell infiltration in the MTC microenvironment, together with its potential prognostic implications, makes it possible for IDO2 to serve as an alternative drug target in cancer immunotherapy and as a new prognostic tool. BioMed Central 2022-11-01 /pmc/articles/PMC9624013/ /pubmed/36319978 http://dx.doi.org/10.1186/s12885-022-10173-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Gu, Pengfei
Ling, Bin
Ma, Weike
Zhang, Jinming
Zhang, Wei
Zeng, Yu
Liu, Yu
Chi, Jiadong
Ruan, Xianhui
Zheng, Xiangqian
Wei, Songfeng
Gao, Ming
Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects
title Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects
title_full Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects
title_fullStr Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects
title_full_unstemmed Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects
title_short Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects
title_sort indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624013/
https://www.ncbi.nlm.nih.gov/pubmed/36319978
http://dx.doi.org/10.1186/s12885-022-10173-7
work_keys_str_mv AT gupengfei indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT lingbin indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT maweike indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT zhangjinming indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT zhangwei indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT zengyu indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT liuyu indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT chijiadong indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT ruanxianhui indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT zhengxiangqian indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT weisongfeng indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects
AT gaoming indoleamine23dioxygenase2immunohistochemicalexpressioninmedullarythyroidcarcinomaimplicationsinprognosisandimmunomodulatoryeffects